Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gefitinib + pembrolizumab
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Gefitinib + pembrolizumab is a combination therapy that pairs gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with pembrolizumab, an anti-programmed death 1 (PD-1) immunotherapy antibody. This combination was evaluated in the phase 1/2 KEYNOTE-021 study for patients with previously untreated stage IIIB/IV EGFR-mutant non-small cell lung cancer (NSCLC). However, the combination was found not to be feasible due to significant liver toxicity, with 5 out of 7 patients (71.4%) developing grade 3/4 liver toxicity, leading to permanent treatment discontinuation in 4 patients.
- Brand names
- KeytrudaIressa
- Other names
- pembrolizumab + gefitinib
02
Targets
EGFR (Epidermal growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on gefitinib + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gefitinib + pembrolizumab.